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Abstract
Orodispersible dosage forms are attractive and innovative drug delivery  
systems that can fulfill individual patient needs, especially in children, elderly and 
among dysphagic patients. Indeed, they rapidly disperse in the mouth upon contact 
with the saliva without the need for water or munching. Examples of such dosage 
forms include orodispersible tablets (ODT), and orodispersible films (ODF). The 
ability to obtain ODF with different dimensions (sizes and thicknesses) makes them 
a suitable for personalized dosing of single or a fixed-dose combination of drugs 
in special patient populations. Several biopolymers are currently being exploited 
in the development of orodispersible dosage forms including alginates due to their 
versatility, availability, naturally occurring, and biosafety profile. This chapter 
provides an appraisal on the various applications of alginates in the preparations 
and their role on the properties of orodispersible dosage forms and highlights future 
perspectives of this very versatile biopolymer for these innovative drug delivery 
systems.
Keywords: alginates, orodispersible films, orodispersible tablets, solid dosage forms, 
personalized therapy
1. Introduction
Orodispersible dosage forms can ameliorate the lack of compliance associated 
with the administration of conventional oral solid-dosage forms (i.e., capsules 
and tablets), or even oral liquid-dosage forms in some patients with swallowing 
difficulties and hence, have the potential to improve medication adherence [1]. 
Indeed, since their appearance into the pharmaceutical market, their development 
has grown gradually, moving from orodispersible tablets (ODT) to orodispersible 
films (ODF) which presents several advantages to completely eliminate the fear of 
chocking in some patients [2, 3]. Moreover, pharmaceutical companies have ampli-
fied research in these dosage forms because they can easily extend their product 
portfolio [4].
ODF have the size of a postage stamp and are individually packed so that 
transportation and patient handling are friendly (Figure 1a). ODF consist of a 
single or multilayer sheet of suitable materials intended to be place in the mouth 
where they rapidly dispersed upon contact with the saliva without need of water or 
munching (Figure 1b). They provide the opportunity to meet the needs of specific 
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subpopulation of patients suffering from a variety of disorders such as dysphagia 
due to pathological or psychological issues. In addition, children and elderly, and 
patients with limited access to water and/or restricted water intake can also benefit 
from their merits [1, 5]. Indeed, the possibility to change size, shape and color of the 
ODF have open new scenarios to prepare small batches for personalization of dose 
in special patient population [6]. Furthermore, ODF can be advantageously used 
as a carrier for other technologies, such as microparticles, nanocrystals and self-
emulsifying systems [5, 7–9], which regulate the drug release patterns and, hence, 
its bioavailability. However, the main ODF pitfalls are related to the limited formula-
tion space [10] which implies a limited drug loading capacity. Secondly, palatability 
drives the compliance for ODF loaded formulations, but the formulation space often 
limits the addition of taste masking agents; even if both bitter and/or astringent 
taste of a drug can be opportunely reduced and/or eliminated [11, 12]. Thirdly, the 
manufacturing process at the industrial scale is mainly based on solvent-casting 
technologies, which require production chains with specialized equipment common 
only to transdermal patches, and therefore, the number of manufacturers world-
wide are limited. Nevertheless, similar to transdermal patches, the dose loaded in an 
ODF is defined by their size and, therefore, the same production chain could be used 
to prepare batches of different drug strengths. Because of this peculiarity, research-
ers are striving to optimize and/or to develop technologies to exploit this peculiarity 
in the extemporaneous compounding of small batches of ODF in a pharmacy setting 
[5]. Since the term “customized dosage form” should be related not only to a tailored 
dose but also to doses on-demand, shape and color of a dosage form [13], this inno-
vation would also allow end-users to easily identify their own medicine, improving 
medication safety and adherence [5].
ODF are generally made up of plasticized hydrocolloids or blends made thereof 
that can be laminated by several techniques and sealed in a moisture-protective 
packages [1]. The active pharmaceutical ingredient (API) can be dissolved or dis-
persed as such or as nanocrystals [7] or loaded into microparticles [8] depending on 
the physicochemical properties of the drug and the desired release pattern. Other 
ODF formulation components are; surfactants, viscosity modifiers, taste-masking 
agents and coloring agents, when required [5, 14, 15].
Among the critical quality attributes of ODF, satisfactory tensile properties 
to guarantee packaging and handling during administration without breakage, 
the disintegration and dissolution in the oral cavity, acceptable taste [5], esthetic 
Figure 1. 
Typical ODF handling from packaging material (a); ideal ODF administration without water (b).
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appearance, and stability of the dosage form itself and the loaded drug(s) need to 
be carefully studied. For instance, the choice of taste-masking agents depends not 
only on the improvement of palatability, but also on their compatibility with other 
formulation components, the possible impact on the drug’s solubility and dissolu-
tion rate, and mechanical properties of the final ODF formulation [5, 12]. This 
chapter provides an appraisal of the various applications of alginates in the design 
and preparation of orodispersible dosage forms as new emerging drug delivery 
systems to overcome some limitations with the conventional solid dosage forms. 
The literature was generated from the Scopus, and PubMed data bases by searching 
single or the combination of the following keywords; alginate, alginates, orodis-
persible film, orodispersible tablet, and orodispersible dosage forms.
2. Preparation methods orodispersible dosage forms
Orodispersible dosage forms can be broadly divided into two based on their 
current commercial availability, i.e., orodispersible tablet (ODT) and orodispersible 
films (ODF). Each of them requires a specialized type of equipment, polymers and 
other formulation additives or excipients since they both have some similarity and 
distinctive peculiarities. The market penetration and commercial success of either 
ODT or ODF depends on the taste of the finished product since the palatability of 
the drug product in orodispersible dosage forms determines patient acceptability and 
subsequently therapeutic success of drug loaded. Therefore, different taste masking 
strategies are employed to mask unpleasant tastes or odors of drugs in orodispersible 
dosage forms such as the use of microencapsulation, complexation technique, using 
taste masking agents such as sweeteners and flavoring agents [3, 14].
Orodispersible tablets (ODT) have the same appearance with the conventional 
tablets. However, unlike the conventional tablets, they are expected to rapidly 
disintegrate within 3 min as a result of their high porous network with the rapid 
penetration of water and/or other fluids. They can be prepared by direct compres-
sion, heat molding technique, or freeze-drying using specific excipients such as 
alginates (Table 1) or their particle engineering products [3].
Orodispersible films (ODF) are mainly prepared by solvent casting technol-
ogy, electrospinning, hot-melt extrusion and more recently by various printing 
techniques for dose personalization [3, 5]. In some cases, a combination of these 
methods is used to obtain an ODF with desired properties or to achieve the desired 
technological and therapeutic objectives. For instance, various printing technolo-
gies have been coupled with other ODF preparation techniques such as solvent 
casting and fused deposition modeling (FDM) 3D printing to prepared ODF 
on-demand. Moreover, hot-melt extrusion (HME) is a solvent-free, continuous 
process. It has a short processing time, suitable for small-scale on-demand prepara-
tion of medicines, and is easy to scale-up. Several thermoplastic polymer-carriers 
and other additives used during extrusion processing are generally regarded to 
be safe for human consumption [28]. Over the last two decades, HME has been 
employed as a novel cost-effective pharmaceutical manufacturing technique of 
different oral solid-dosage forms. It has been suitably used in the preparation of 
immediate-release, novel taste-masked and abuse deterrence tablets formulations 
[28, 29], chrono-modulated drug delivery systems [30], for immediate release 
formulation of ODF [2, 3], and ODF containing poorly water soluble and highly 
polymorphic drugs [31–33]. Thus, the combination of HME and additive printing 
technology has been shown to offer several advantages [6, 33]; first, the ability 
to fabricate immediate-release, modified-release, and other novel drug delivery 
















Type of alginate used Role of the alginate in 
the formulation
Special notes Reference
ODF Sodium alginate and 
alginate oligosaccharides
Drug carriers • Both placebo and posaconazole mucoadhesive films formulations containing the 
sodium alginate and alginate oligosaccharides exhibited antifungal properties on 
Candida species.
[16]
ODF Alginate hexyl amide 
derivative
Film-forming polymer • New film-forming alginate hexyl amide derivative was prepared.
• Repaglinide bioavailability was enhanced by the new film-forming alginate 
derivative.
[17]
ODF Sodium alginate Film-forming polymer • Nebivolol hydrochloride was loaded in the ODF using solvent casting technique.
• Croscaramellose sodium was used as super-disintegrant in the formulation
[18]
ODF Sodium alginate Film-forming polymer • Fluconazole mucoadhesive films were prepared to provide prolonged release of the 
drug for topical treatment of candidiasis.
• Sodium alginate was used alone or in combination with sodium carboxymethyl 
cellulose, Carbopol, and polycarbophil.
[19]
ODF Sodium alginate Film-forming polymer • Terbutaline sulphate sublingual films were prepared by solvent casting with the 
sodium alginate singly or in combination with xanthan gum, Carbopol, or HPMC 
E5 and maltodextrin.
• The films disintegrate rapidly with faster absorption rate compared to conven-
tional tablet from the pharmacokinetic study on healthy human volunteers.
• The formulated films can be use in the management of acute episodes of asthma 
attacks.
[20]
ODF Sodium alginate Film-forming polymer • Levocetirizine HCl film was prepared with the addition of sodium starch glycolate 
as disintegrating agent.
• A full 32 factorial design was applied to optimize the concentration of the sodium 
alginate and disintegrant
[21]
ODF Sodium alginate Film-forming polymer • Piroxicam ODF were prepared by solvent casting. [22]
ODF Sodium alginate Disintegrant • Sildenafil citrate was loaded in the ODF resulted in decreased disintegration time 










































Type of alginate used Role of the alginate in 
the formulation
Special notes Reference
ODT Calcium alginate Superdisintegrant • Mini ODT were prepared by direct compression using mannitol and MCC as filler/
binder excipients.
• Addition of the calcium alginate have shown to improve the disintegration time of 
the mini ODT.
[24]
ODT Alginic acid and calcium 
alginate
Superdisintegrant • Xerogels containing alginic acid, or calcium alginate and a mixture of both were 
isolated using oven and rotary evaporation methods.
• Mini ODT were prepared with the xerogels developed from the alginates with 
improved wettability and ultimately rapid disintegration.
[25]
ODT Sodium alginate Taste masking agent • Solid dispersion was used to deter the taste of fexofenadine HCl by controlling the 
rate of drug release in the saliva pH
[26]
ODT Sodium alginate Superdisintegrant • Meclizine HCl ODT was formulated by direct compression using sodium alginate 
as such or in combination with xanthan gum to reenforce the superdisintegrant 
properties of the former and to improve the mechanical quality of the tablets.
[27]
HPMC: hydroxypropyl methyl cellulose; MCC: microcrystalline cellulose; HCl: hydrochloride.
Table 1. 
Applications of alginates in orodispersible dosage forms.
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thirdly, the ability to load drugs that are prone to polymorphic transformation in 
the present of water or solvent system [33], and finally, the ability to reduces several 
unit-operations related to traditional manufacturing process such as  granulation, 
milling, sieving, compressing, and coating. Hence, they are very efficient and 
economical, in particular for small-scale on-demand personalized formulations 
[34, 35]. Moreover, additive printing technology combines digital design, manufac-
turing, and controls together, which is an accurate, timesaving, continuous process 
to meet individual patient needs [28, 36]. Therefore, the combination of HME and 
additive printing can be applied as a fabrication tool in the field of digital health 
for the remote manufacture and dispensing of personalized orodispersible dosage 
forms having shapes, sizes, and doses that are optimized for a particular patient or 
group of patients based on their needs [28]. Consequently, the therapeutic efficacy 
and medication adherence can be enhanced owing to the flexibility and autonomy 
of the treatment process provided by the combination of these technologies.
3.  Application of additive manufacturing in personalized orodispersible 
dosage forms
The concept of personalized therapy is gaining attention in recent years with 
the aim of providing appropriate drug(s), dosage regiments, and/or medical care 
based on the individual patient’s peculiarities such as age, medical history, diagnostic 
results, or genetic information aiming to minimize medication errors such as drug 
interactions, side effects, and adverse drug reactions and to obtain maximum thera-
peutic benefits [37, 38]. Technologically speaking, personalized therapy is centered 
towards personalized dosing, or dose precision and providing age-appropriate 
dosage forms capable of addressing patients’ specific requirements. As an example, 
in the case of children, it has been estimated that the availability of authorized and 
commercially available medicine for children varies between 48% and 54% of all 
approved medicines and that up to 50% of pediatric patients receive an unlicensed or 
off-label prescription [39]. Indeed, it has been recognized that children are unable to 
or have difficulties with swallowing tablets or capsules. Moreover, crushing tablets, 
opening capsules, or mixing powders to extemporaneously prepare the required dose 
with liquids may lead to dose variability, contamination, drug instability, taste and 
solubility problems, and other consequences for safety of the patient and the efficacy 
of the treatment. It is therefore of paramount importance to develop age-appropriate 
dosage forms, as pointed out by the World Health Organization’s (WHO) initiative 
‘better medicines for children’. Therefore, personalized orodispersible dosage forms 
such as ODF or ODT prepared on-demand by additive printing technologies can 
potentially legitimized personalized and precise dosing in patients with special needs.
Additive printing presents a promising future for the point-of-care manufacturing 
of medicines. Technologies such as two-dimensional (2D) and three-dimensional (3D) 
printing appeared capable of producing individualized oral drug delivery systems, such 
as ODF with customizable drug dose strengths, and in some cases with pre-defined 
drug release patterns [40, 41]. The use of computer-aided design (CAD) software to 
design different dimensions of a 3D objects prior to printing displays the potential of 
3D printing for the concept of precision dosing of active pharmaceutical ingredients 
(APIs) [41]. Despite the significant technological advancements made so far during the 
21st century on conventional pharmaceutical manufacturing processes, especially being 
cost-effective for large-scale industrial production, they can be inherently labour inten-
sive, time-consuming, and dose inflexible. This poses significant challenges for certain 
groups of patients that require tailored dosing (particularly among pediatrics and 
geriatrics) or for certain medicines that require frequent dose adjustments (e.g., drugs 
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with narrow therapeutic index). Therefore, to achieve pharmacotherapeutic goals with 
greater efficacy, quality and safety in patients with special needs, the use of innovative 
approach such as additive printing technologies are required within pharmaceutical 
field to facilitate the preparation of small-scale, on-demand and dose-flexible formula-
tions such as ODF. Additive printing process which enables the design of a customized 
oral dosage forms is triggering a paradigm shift in the way medicines are manufactured 
and administered [42]. Furthermore, this process could make possible the printing 
of medicines in pandemic outbreak areas to mitigate drug shortages and supply chain 
disruptions, and potential for making available printing of medicines in war zones, in 
clinical trials in hospital settings [43, 44] and preparation of individualized fixed-dose 
combination products [44–46]. Perhaps, the current regulatory landscape on additive 
printing is flexible enough to accommodate this technology for mass production in 
addition to its benefits in extemporaneous compounding of medicines. Thus, according 
to United States Food and Drug Administration’s (FDA) guidelines for additive printing, 
once the printing device/equipment is optimized, the first step is the design process, 
which can include a standard design with distinct pre-specified dimensions, in the case 
of ODF for instance; the design of an ODF area and desired thickness which ultimately 
defined the dose of loaded API according to individual patient needs. Once the device 
design is converted to a digital file, the software workflow phase begins, and that file 
is further processed to prepare it for printing (Figure 2), at this stage, the printing 
parameters are optimized. Concurrently with this step, material controls are established 
for materials used in the printing of the dosage form (i.e., rheological evaluation, and 
printability). After printing is complete, post-processing of the built dosage form (e.g., 
packing and labelling) takes place. After post-processing, the final finished dosage form 
is ready for characterization [47].
4. Applications of alginates in orodispersible dosage forms
Alginate is a natural polymer used widely in pharmaceutical, food, and bio-
medical applications because of its biodegradable and biocompatible properties. 
Alginate and its derivatives are considered low or nontoxic, and non-immunogenic 
Figure 2. 
Schematic flow chart of additive printing process from design and material selection to the finished product 
characterization.
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hence suitable for human consumption [48, 49]. Moreover, various alginate salts 
(ammonium, calcium, sodium, potassium) and propylene glycol alginate deriva-
tives are generally regarded as safe (GRAS) ingredients, for oral administration 
by the FDA. Like many other pharmaceutical products, the selection of excipients 
for orodispersible dosage forms requires thoughtful consideration based on the 
peculiar properties of the dosage form itself such as rapid disintegration, drug-
excipient compatibility, biocompatibility with body fluids such as saliva and GIT 
fluids. Therefore, alginate and its derivatives have found different applications in 
the design and preparation of orodispersible dosage forms. As an example, sodium 
alginate has been used as an orodispersible film-forming polymer to provide 
mucoadhesive properties of the films or to increased drug loading or both. These 
applications are mostly accomplished with the sodium alginate alone to load poorly 
soluble drugs in ODF [22], or in combination with other polymers such as polyvinyl 
alcohol, chitosan, Carbopol 974P, and sodium carboxymethyl cellulose [22, 23, 50]. 
Various ODF formulations applying the uniqueness of alginates to provide different 
functions in the dosage form are exemplified in (Table 1). Indeed, it is worthy to 
note that, alginate-based orodispersible films have shown high tensile strength and 
high hydrophilicity with disintegration time within few seconds [20, 51]. Hence, the 
use of alginate in ODF represent good systems to formulate orodispersible dosage 
forms, promoting hydrophilic properties and ultimately suitable disintegration time 
which is fundamental quality for ODF. Nevertheless, few studies have explored 
alginate as a film-forming agent in ODF preparations either singly or in combina-
tion with other polymers. Thus, highlighting missing gaps to explore in discovering 
other potentials of alginates in ODF formulations [51].
Similarly, various alginate derivatives have also found application in the formu-
lation of ODT where they serve different functionality. For instance, alginic acid 
and its salts have been used as disintegrants, super-disintegrants, and/or fillers in 
ODT formulations [24, 25]. Soulairol and co-workers developed xerogels contain-
ing alginic acid, calcium alginate or the combination thereof in the design and 
formulation of orodispersible mini tablets where they have been shown to provide 
enhanced super-disintegrant properties [25]. Further, Yehia et al., employed the 
use of sodium alginate as a taste-masking agent in ODT through solid dispersion 
technique. The authors succeeded in masking the taste of fexofenadine hydrochlo-
ride by controlling the rate of drug release in the saliva pH as confirmed by healthy 
human volunteers [26]. A summary of the various applications of alginates in ODT 
is also provided in (Table 1).
5. Conclusion
Alginates have wide range of application in the design and preparation of orodis-
persible dosage forms. The choice of a particular alginate type depends on several 
factors, such as the type of the orodispersible dosage form to be prepared, i.e., ODT 
or ODF, the physicochemical properties of the alginate and that of the drug itself, 
and the nature of the release pattern of the loaded drug(s). Most of the alginate’s 
applications in ODF and ODT are in the solvent casting and direct compression 
method for their preparations, respectively. Thus, exploring alginates applications 
in the preparation of these dosage forms by other techniques such as 3D printing, 
freeze drying, and particle engineering can open new scenarios in their application 
in the development of these innovative drug delivery systems.
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